



BC Centre for Disease Control
Provincial Health Services Authority

Communicable Diseases and Immunization Service
655 West 12th Avenue
Vancouver, BC V5Z 4R4

Tel 604.707.2548
Fax 604.707.2515
www.bccdc.ca

Date: January 21, 2022

Administrative Circular: 2022:05

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products**

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 mRNA Vaccine COMIRNATY® (Pfizer-BioNTech) (Adult/Adolescent)

Precautions: The content regarding myocarditis/pericarditis has been revised per the [NACI summary](#) to allow for further vaccination of individuals with a history compatible with pericarditis or confirmed myocarditis provided that certain conditions are met.

Please remove page numbers: 1-6 dated January 14, 2022
Please add new page numbers: 1-6 dated January 21, 2022

COVID-19 mRNA Vaccine COMIRNATY® (Pfizer-BioNTech) (Pediatric)

Precautions: The content regarding myocarditis/pericarditis has been revised per the [NACI summary](#) to allow for further vaccination of individuals with a history compatible with pericarditis or confirmed myocarditis provided that certain conditions are met.

Please remove page numbers: 1-5 dated January 14, 2022
Please add new page numbers: 1-6 dated January 21, 2022

COVID-19 mRNA Vaccine SPIKEVAX™ (Moderna)

Precautions: The content regarding myocarditis/pericarditis has been revised per the [NACI summary](#) to allow for further vaccination of individuals with a history compatible with pericarditis or confirmed myocarditis provided that certain conditions are met.

Please remove page numbers: 1-5 dated January 14, 2022
Please add new page numbers: 1-5 dated January 21, 2022

Page 1 of 2

Addendum: Post-Immunization Observation Period

[Guidance](#) has been developed regarding a reduced post-immunization observation period following administration of third doses of COVID-19 vaccine on a temporary basis during the pandemic. Specific conditions apply and are outlined in this document.

Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated December 2021 and replace with the enclosed updated Title Page and Table of Contents dated January 2022.

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,



Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health &
Wellness, PHSa & Deputy Provincial
Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population &
Public Health Division:

Brian Sagar
Senior Director Communicable
Disease, Population and Public Health
Division

Bernard Achampong
Executive Director,
Public Health, Planning and Prevention,
Population and Public Health Division